Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
Public ClinicalTrials.gov record NCT03460483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.
Study identification
- NCT ID
- NCT03460483
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 1,001 participants
Conditions and interventions
Interventions
- Genetic Counseling Other
- Genetic Testing Other
- Laboratory Biomarker Analysis Other
- Mutation Carrier Screening Procedure
Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2018
- Primary completion
- Jun 14, 2025
- Completion
- Jun 14, 2025
- Last update posted
- Oct 2, 2025
2018 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 1
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Summa Akron City Hospital/Cooper Cancer Center | Akron | Ohio | 44304 | — |
| Aultman Health Foundation | Canton | Ohio | 44710 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| TriHealth Cancer Institute-Westside | Cincinnati | Ohio | 45245 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Ohio Health | Columbus | Ohio | 43214 | — |
| Mercy Health - St. Vincent Medical Center | Toledo | Ohio | 43608 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03460483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03460483 live on ClinicalTrials.gov.